Study Finds Poor Evidence For Many FDA Breakthrough Devices

By Jessica Karins / October 10, 2025 at 4:52 PM

A study examining the products approved through FDA’s breakthrough devices program found FDA usually did not require postmarket studies for devices approved through the pathway even when they relied on surrogate endpoints or lacked statistical testing, raising questions about whether the program is meeting its objectives.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.